Solara Active Pharma Sciences Reports Mixed Financial Results for Q1 FY25

Solara Active Pharma Sciences, a smallcap pharmaceutical company, has recently announced its financial results for the quarter ending June 2024. The company’s stock has been given a ‘Sell’ call by MarketsMOJO.

According to the financial report, Solara Active has shown a flat performance in the quarter, with a score of 0 compared to -9 in the previous quarter. However, there are some positive aspects to the company’s financials.

The operating profit (PBDIT) for the quarter was the highest in the last five quarters at Rs 41.92 crore, indicating a positive trend in the near term. The operating profit margin was also at its highest in the last five quarters at 11.53%, showing an improvement in the company’s efficiency.

The earnings per share (EPS) for the quarter was also the highest in the last five quarters at Rs -3.20, indicating an increase in profitability and higher earnings for shareholders. Additionally, the debtors turnover ratio for the half-yearly period was at its highest in the last five periods at 3.80 times, showing that the company has been able to settle its debtors faster.

However, there are also some areas of concern in Solara Active’s financials. The interest cost for the half-yearly period has grown by 23.59% compared to the previous period, indicating increased borrowings. The debt-equity ratio for the half-yearly period was also at its highest in the last five periods at 1.08 times, suggesting that the company may be borrowing more to fund its operations and its liquidity situation may be stressed.

Overall, Solara Active’s financial performance for the quarter ending June 2024 has been flat, with some positive and negative aspects. Investors should carefully consider these factors before making any investment decisions.